DS-8201的关键性研究中对脑转移患者的疗效做了深入的分析,结果也非常亮眼。DS-8201后线治疗脑转的PFS居然还可达到18.1个月之长,实为不易。 上市只是迈出可及性的第一步,接地气的价格才是医患更加关心的。近期,赫赛莱正式到货后,“放心莱”也正式启动,为HER2阳性患者带来价格福利。 重磅药物赫赛莱®(注射用恩美曲妥珠单抗)正式到货,“放心莱”点燃乳腺癌患者治愈希望! 期望越来越多的重磅好药早日上市,并且价格越来越亲民,让乳腺癌患者获益! 责任编辑:乳腺癌互助君参考链接:1.Ian Krop, Cristina Saura, Toshinari Yamashita, et al. Trastuzumab Deruxtecan (DS-8201) in HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: DESTINY-Breast01 Study . 2019 SABCS.2.S. Modi, C. Saura, T. Yamashita et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.20193.ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer, Retrieved March 25, 20204.Modi Shanu,Saura Cristina,Yamashita Toshinari et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.[J] .N. Engl. J. Med., 2020, 382: 610-621.5.von Minckwitz G, Huang C S, Mano M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. New England Journal of Medicine, 2019, 380(7): 617-628.